Huons Meditech, a medical device manufacturer under Huons Group, is intensifying its global marketing efforts by attending major international conferences.
The company announced on Tuesday that it highlighted its technology and competitiveness at the Congress of Société Internationale d'Urologie 2024 (SIU 2024) in New Delhi, India.
Founded in 1907, the Société Internationale d'Urologie (SIU) is the world’s foremost urology specialty society. It is dedicated to discussing research and technological advancements in urological diseases and treatments.
Each year, thousands of urologists from over 100 countries gather at SIU to share new technologies, the latest treatment methods, and research outcomes, representing cutting-edge trends in the global urology field.
At SIU 2024, Huons Meditech showcased the advanced capabilities of its extracorporeal shock wave lithotripsy device, URO-UEMXD.
The URO-UEMXD addresses the limitations of traditional X-ray equipment by integrating a shock wave head with an inline ultrasound probe, a first in Korea. This ultrasound probe allows for the diagnosis and treatment of permeable urinary stones. Unlike conventional X-rays, ultrasound can detect both permeable and non-permeable stones, enhancing diagnostic accuracy and expanding treatment possibilities.
At the event, Huons Meditech, in partnership with India’s Vasu Group, presented the URO-UEMXD, a lithotripsy device designed to break down urinary stones in the kidneys, receiving an enthusiastic response from attendees.
Vasu Group, with its extensive global network, supplies various medical devices and pharmaceuticals worldwide.
Through this collaboration, Huons Meditech and Vasu Group aim to actively expand their reach in the global urology market.
Additionally, Yoon Ha-na, Korea’s first female urologist and a professor of urology at Ewha Womans University Medical Center, delivered a presentation on current trends in extracorporeal shock wave lithotripsy (ESWL) for urolithiasis.
Yoon highlighted that advancements in technology have significantly enhanced treatment effectiveness and patient convenience. She also discussed the safety and efficiency of ESWL, drawing on various research findings.
Earlier, Huons Meditech took part in the International Congress of ASLS & Perdaweri Banten (ICAP 2024) in Jakarta, Indonesia, aiming to strengthen its presence in the global aesthetics market.
Lee Jin-suk, CEO of Huons Meditech, stated that the company is prioritizing overseas marketing to boost its global competitiveness, including participation in international conferences.
"Through this participation, we had a valuable opportunity to introduce the excellence of our products to the Indian and Indonesian medical device markets," he said. "We will continue to actively pursue overseas markets through close collaboration with global partners."
Related articles
- Huons Global marks record-high Q2 sales of ₩209 billion
- Huons Meditech showcases key products at FIME 2024
- Huons Meditech showcases flagship devices at Hospitalar 2024 in Brazil
- Huons Meditech names Lee Jin-suk as new CEO
- Huons reports 6.3% revenue growth in Q3, focuses on diabetes devices, biopharma expansion
- Huons Biopharma partners with VERNI Aesthetics to advance fat-decomposition injection MRC101
- Huons Biopharma partners with KIST to develop dry macular degeneration eye drops
- Huons Meditech surpasses 20,000 units sold in Dermashine product line
- Huons Meditech expands its global presence at Arab Health 2025
- Huons Meditech to unveil advanced shockwave, aesthetic devices at KIMES 2025
- Huons Meditech enhances urology with new shockwave device for prostatitis
